This technology describes four chemical compounds that are capable of inhibiting the ID2/VHL interaction for downstream inhibition of tumor growth and angiogenesis.
Tumor hypoxia is linked with poor prognosis, malignancy, and treatment resistance. Hypoxia-inducible factor α (HIFα) plays a role in the transcriptional response to hypoxic stress and is highly expressed in tumor cells. In hypoxic conditions, ID2 interacts with von Hippel-Lindau (VHL) tumor suppressor protein and inhibits proteasomal degradation of HIFα, promoting tumor growth, angiogenesis, and cell proliferation.
The technology presents four chemical compounds that can inhibit the interaction between ID2 and VHL, leading to the degradation of HIFα. These compounds show a dose-dependent response and can achieve a 50-90% inhibition of ID2/VHL interaction. These compounds could be utilized as potential therapeutic agents for treating various cancers, including gliomas, by blocking tumor growth and angiogenesis.
IR CU17182, CU16166
Licensing Contact: Kristin Neuman
